Advertisement

Neurotoxicity Research

, Volume 9, Issue 2–3, pp 145–148 | Cite as

Botulinum toxin therapy for cervical dystonia

  • Joseph Jankovic
Article

Abstract

Cervical dystonia (CD) is the most common form of focal dystonia treated with botulinum toxin (BoNT) injections. BoNT has been shown in numerous clinical trials to correct the abnormal posture and movement and to markedly reduce pain associated with CD. In addition, BoNT has favorably modified the natural history of the disease by preventing contractures and other complications of CD, such as secondary degenerative changes of the cervical spine and associated radiculopathy. In a long-term follow-up of patients treated for up to 20 years, the duration of response appears to be sustained and the risk of immunoresistance due to blocking antibodies is relatively small. This review provides and update on the treatment of CD with BoNT type A (BOTOX®, Dysport®, Xeomin®) and BoNT type B (Myobloc™, NeuroBloc®).

Keywords

Dystonia Cervical Botulinum toxin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benecke R, WH Jost, P Kanovsky, E Ruzicka, G Comes and S Grafe (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.Neurology 64, 1949–1951.PubMedCrossRefGoogle Scholar
  2. Berman B, L Seeberger and R Kumar (2005) Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.Mov. Disord. 20, 233–237.PubMedCrossRefGoogle Scholar
  3. Comella CL, J Jankovic, S Daggett, J Mordaunt and MF Brin (2004) Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia.Neurology 62 (Suppl. 5), A511.Google Scholar
  4. Comella CL, J Jankovic, KM Shannon, J Tsui, M Swenson, S Leurgans and W Fan Dystonia Study Group (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 65, 1423–1429.PubMedCrossRefGoogle Scholar
  5. Consky ES and AE Lang (1994) Clinical assessments of patients with cervical dystonia, In:Therapy with Botulinum Toxin (Jankovic J and M Hallett, Eds.) (Marcel Dekker: New York, NY),pp 211–237.Google Scholar
  6. Diamond A, J Shahed, S Azher, K Dat-Vuong, R Simpson and J Jankovic (2005) Globus pallidus deep brain stimulation in dystonia.Mov. Disord. 2005 Dec 9; [Epub ahead of print].Google Scholar
  7. Dressler D and R Benecke (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.Eur. Neurol. 49, 34–38.PubMedCrossRefGoogle Scholar
  8. Dressler D and H Bigalke (2005) Botulinum toxin type Bde novo therapy of cervical dystonia: frequency of antibody induced therapy failure.J. Neurol. 252, 904–907.PubMedCrossRefGoogle Scholar
  9. Dressler D, M Lange and H Bigalke (2005) Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.Mov. Disord. 20, 1617–1619.PubMedCrossRefGoogle Scholar
  10. Ertekin C, I Aydogdu, Y Secil, N Kiylioglu, S Tarlaci and T Ozdemirkiran (2002) Oropharyngeal swallowing in craniocervi-cal dystonia.J. Neurol. Neurosurg. Psychiatry 73, 406–411.PubMedCentralPubMedCrossRefGoogle Scholar
  11. Factor SA, ES Molho, S Evans and PJ Feustel (2005) Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.Mov. Disord. 20, 1152–1160.PubMedCrossRefGoogle Scholar
  12. Jankovic J (2004a) Treatment of cervical dystonia with botulinum toxin.Mov. Disord. 19 (Suppl. 8), S109A-S115A.CrossRefGoogle Scholar
  13. Jankovic J (2004b) Botulinum toxin in clinical practice.J. Neurol. Neurosurg. Psychiatry 75, 951b-957b.CrossRefGoogle Scholar
  14. Jankovic J, KD Vuong and J Ahsan (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology 60, 1186–1188.PubMedCrossRefGoogle Scholar
  15. Jankovic J, A Esquenazi, D Fehling, F Freitag, AM Lang and M Naumann (2004) Evidence-based review of patient reported outcomes with botulinum toxin type A.Clin. Neuropharmacol. 27, 234–244.PubMedCrossRefGoogle Scholar
  16. Jankovic J, J Tsui and C Bergeron (2005a) Prevalence of cervical dystonia and spasmodic torticollis in the United States.Mov. Disord. 20 (Suppl. 10) S22a.Google Scholar
  17. Jankovic J, CB Hunter and the BOS Study Group (2005b) Botulinum toxin type B observational study.Ann. Neurol. 58 (Suppl. 9) S54.Google Scholar
  18. Marchetti A, R Magar, L Findley, JP Larsen, Z Pirtosek, E Ruzicka, R Jech, J Slawek and F Ahmed (2005) Retrospective evaluation of the dose of Dysport® and BOTOX® in the management of cervical dystonia and blepharospasm: The REAL DOSE study.Mov. Disord. 20, 937–944.PubMedCrossRefGoogle Scholar
  19. Mejia NI, KD Vuong and J Jankovic (2005) Long-term botulinum toxin efficacy, safety and immunogenicity.Mov. Disord. 20, 592–597.PubMedCrossRefGoogle Scholar
  20. Naumann M and J Jankovic (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis.Curr. Med. Res. Opin. 20, 981–990.PubMedCrossRefGoogle Scholar
  21. Riski JE, J Horner and BS Nashold Jr (1990) Swallowing function in patients with spasmodic torticollis.Neurology 40, 1443–1445.PubMedCrossRefGoogle Scholar
  22. Tintner R, R Gross, UF Winzer, KA Smalky and J Jankovic (2005) Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial.Neurology 65, 765–767.PubMedCrossRefGoogle Scholar
  23. Truong D, DD Duane, J Jankovic, C Singer, LC Seeberger, CL Comella, MF Lew, RL Rodnitzky, FO Danisi, JP Sutton, PD Charles, RA Hauser and GL Sheean (2005) Efficacy and safety of botulinum type A toxin (Dysport®) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.Mov. Disord. 20, 783–791.PubMedCrossRefGoogle Scholar
  24. Vidailhet M, L Vercueil, JL Houeto, P Krystkowiak, AL Benabid, P Cornu, C Lagrange, S Tezenas du Montcel, D Dormont, S Grand, S Blond, O Detante, B Pillon, C Ardouin, Y Agid, A Destee, P Pollak and the French Stimulation du Pallidum Interne dans la Dystonie (SPIDY) Study Group (2005) Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia.N. Engl. J. Med. 352, 459–467.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  1. 1.Department of Neurology, Baylor College of MedicineParkinson’s Disease Center and Movement Disorders ClinicHoustonUSA

Personalised recommendations